Billets de Michelle Dawson

Billet publié sur Bluesky le 25/01/2024 12:39

Bluesky Publication avec DOI crossref Extrait cité dans le billet Question posée par Dawson dans le billet Lien intégré au billet Termes sur l’autisme

Liens cités structurés

1 ressource citée

Publication avec DOI Récupéré Publication crossref

Inge Kamp-Becker (2024). Autism spectrum disorder in ICD-11—a critical reflection of its possible impact on clinical practice and research. Molecular Psychiatry, 29(3), 633-638. Springer Science and Business Media LLC.

Date de publication
25/01/2024
Identifiant
10.1038/s41380-023-02354-y
Auteurs
Inge Kamp-Becker
Source
Molecular Psychiatry
Détails
29(3), 633-638
Type de référence
article
Éditeur
Springer Science and Business Media LLC
Source de métadonnées
crossref

Résumé

Abstract This perspective article compares and contrasts the conceptualization of Autism Spectrum Disorder (ASD) in ICD-11 and DSM-5. By guiding the user through the ICD-11 text, it is argued that, in contrast to DSM-5, ICD-11 allows a high variety in symptom combinations, which results in an operationalization of ASD that is in favor of an extreme diverse picture, yet possibly at the expense of precision, including unforeseeable effects on clinical practice, care, and research. The clinical utility is questionable as this conceptualization can hardly be differentiated from other mental disorders and autism-like traits. It moves away from an observable, behavioral, and neurodevelopmental disorder to a disorder of inner experience that can hardly be measured objectively. It contains many vague and subjective concepts that lead to non-falsifiable diagnoses. This bears a large danger of false positive diagnoses, of further increased prevalence rates, limitations of access to ASD-specific services and of increasing the non-specificity of treatments. For research, the hypothesis is that the specificity of ASD will be reduced and this will additional increase the already high heterogeneity with the effect that replication of studies will be hampered. This could limit our understanding of etiology and biological pathways of ASD and bears the risk that precision medicine, i.e., a targeted approach for individual treatment strategies based on precise diagnostic markers, is more far from becoming reality. Thus, a more precise, quantitative description and more objective measurement of symptoms are suggested that define the clinical ASD phenotype. Identification of core ASD subtypes/endophenotypes and a precise description of symptoms is the necessary next step to advance diagnostic classification systems. Therefore, employing a more finely grained, objective, clinical symptom characterization which is more relatable to neurobehavioral concepts is of central significance.

Auteur·ices de l’étude dans cette référence citée